FDA calendar · May 2024 · built from SEC filings

PDUFA dates May 2024: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

2 PDUFA dates fell in May 2024: CARDAMYST (May 2024), ABEO (May 25). The FDA calendar also recorded 18 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in May 2024

2 PDUFA target action dates in May 2024, soonest first, each linked to the SEC filing or FDA page that disclosed it. Data as of .
PDUFA dateCompanyTickerDrugIndicationSource
May 2024Milestone Pharmaceuticals Inc.MISTCARDAMYST (etripamil)SEC 8-K Exhibit 99.1, filed 2025-03-13
May 25, 2024ABEONA THERAPEUTICS INC.ABEONot namedSEC Form 10-Q, filed 2024-11-14

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

May 2024: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
May 2024Month disclosedCARDAMYST (etripamil)MISTNDA/BLA accepted—CompletedSEC 8-K Exhibit 99.1
May 2024Month disclosedAUSTEDO (deutetrabenazine)TEVAFDA approval—ApprovedSEC 8-K Exhibit 99.1
May 16, 2024Imdelltra (tarlatamab-dlle)AMGNFDA approvalTo treat extensive stage small cell lung cancerApprovedFDA Novel Drug Approvals
May 16, 2024Benlysta (belimumab)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
May 25, 2024—ABEONDA/BLA accepted—CompletedSEC Form 10-K
May 28, 2024Bkemv (eculizumab-aeeb)AMGNFDA approval—ApprovedopenFDA Drugs@FDA
May 29, 2024Retevmo (selpercatinib)LLYLabel expansion—ApprovedopenFDA Drugs@FDA
May 31, 2024Cefazolin In Dextrose (cefazolin sodium)BAXLabel expansion—ApprovedopenFDA Drugs@FDA

May 2024: dated readouts

DateDrugCompanyEventIndicationStatusSource
May 2024Month discloseduproleselanCBIOTopline readout—MixedSEC Form 10-Q
May 2024Month disclosed—CTXRTopline readout—Positivesec_424b
May 2024Month disclosed—INSMTopline readout—PositiveSEC Form 10-Q
May 2024Month disclosedFG-3246KYNBInterim readoutmCRPCPositiveSEC Form 10-Q
May 2024Month disclosed—ORGOTopline readout—Met primary endpointSEC Form 10-Q
May 2024Month disclosedpariglasgene brecaparvovec (DTX401)RARETopline readoutaged eight years and olderPositiveSEC Form 10-K
May 2024Month disclosed—SABSTopline readout—Positivesec_424b
May 3, 2024ABP-450AEONInterim readout—Missed primary endpointSEC Form 10-Q

May 2024: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
May 2024Month disclosedsabirnetug (ACU193)ABOSTrial start—CompletedSEC Form 10-K
May 15, 2024andersenNMADTrial startovarian clear cell carcinomaCompletedSEC Form 10-Q

2 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps May 2024. They are on each drug page and in the calendar API.

Questions

What PDUFA dates are in May 2024?

2 PDUFA dates fell in May 2024: CARDAMYST (May 2024), ABEO (May 25). The FDA calendar also recorded 18 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.